Skip to content
Colistin
Coly-mycin (colistin) is a protein pharmaceutical. Colistin was first approved as Coly-mycin s on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Coly-mycin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Colistin sulfate
Tradename
Company
Number
Date
Products
COLY-MYCIN SPfizerN-050355 DISCN1982-01-01
1 products
Hide discontinued
Colistin sulfate
+
Hydrocortisone acetate
+
Neomycin sulfate
+
Thonzonium bromide
Tradename
Company
Number
Date
Products
COLY-MYCIN SEndoN-050356 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
coly-mycinNew Drug Application2018-12-03
cortisporin tcNew Drug Application2019-01-15
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA10: Colistin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XB: Polymyxins
— J01XB01: Colistin
HCPCS
No data
Clinical
Clinical Trials
79 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970F14317—3342
Substance-related disordersD019966EFO_0003890F131111—3
AlcoholismD000437EFO_0003829F10.1———1—1
EpistaxisD004844EFO_0003895R04.0———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Opioid-related disordersD009293EFO_0005611F11—1———1
Human influenzaD007251EFO_0007328J11.111———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute coronary syndromeD054058EFO_00056721————1
Chest painD002637HP_0100749R07.91————1
PharmacokineticsD0105991————1
Healthy volunteers/patients—1————1
Impulsive behaviorD0071751————1
Substance withdrawal syndromeD013375EFO_00058001————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
LactationD007774————11
Pituitary acth hypersecretionD047748EFO_1001110E24.0————11
PainD010146EFO_0003843R52————11
Respiratory insufficiencyD012131HP_0002093J96.9————11
AnesthesiaD000758————11
Dental implantsD015921————11
Dental impression techniqueD003761————11
ObesityD009765EFO_0001073E66.9————11
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCOLISTIN
INNcolistin
Description
Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
Identifiers
PDB—
CAS-ID1066-17-7
RxCUI2709
ChEMBL IDCHEMBL2221249
ChEBI ID—
PubChem CID5311054
DrugBankDB00803
UNII IDZ67X93HJG1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 26,779 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,890 adverse events reported
View more details